EBV treatment market
Feb 17, 2023
Changing Landscape of EBV-associated Diseases Treatment: Is T-cell Immunotherapy the Answer?
Epstein–Barr virus (EBV), also known as human herpesvirus 4 (HHV-4), was discovered in the 1960s as an inescapable virus that infects almost 95% of the world’s population and causes nearly 1% of all cancers. Besides, the virus is a leading cause of infectious mononucleosis (IM) and is associated with different subt...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
